Evogene Ltd. (NASDAQ:EVGN – Get Free Report) shares passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $0.59 and traded as low as $0.3801. Evogene shares last traded at $0.3862, with a volume of 37,674 shares.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a report on Friday, October 2nd. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Evogene has an average rating of “Sell”.
View Our Latest Report on Evogene
Evogene Trading Down 3.4%
The company has a fifty day moving average of $0.50 and a two-hundred day moving average of $0.59. The stock has a market capitalization of $3.37 million, a price-to-earnings ratio of -0.42 and a beta of 1.44.
Insiders Place Their Bets
In other Evogene news, Director Leon Recanati acquired 460,000 shares of Evogene stock in a transaction dated Tuesday, August 11th. The stock was bought at an average cost of $0.64 per share, with a total value of $294,400.00. Following the completion of the transaction, the director owned 1,343,886 shares of the company’s stock, valued at $860,087.04. The trade was a 52.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.40% of the stock is currently owned by insiders.
Evogene Company Profile
Evogene Ltd. is an Israel-based computational biology company that develops products and technologies for the life sciences and agriculture industries. Founded in 1999 and headquartered in Rehovot, Israel, the company uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and machine-learning tools to identify and develop novel biological products.
Evogene’s activities have included agricultural solutions such as crop-protection products, bio-stimulants and microbiome-based technologies.
Recommended Stories
- Five stocks we like better than Evogene
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
